Misplaced Pages

Alitretinoin

Clinical data
Trade names	Panretin (gel), Toctino (oral)
AHFS/Drugs.com	Monograph
MedlinePlus	a601012
License data	EU EMA: by INN US DailyMed: Alitretinoin
Routes of administration	Topical, by mouth
ATC code	D11AH04 (WHO) L01XF02 (WHO)
Legal status
Legal status	UK: POM (Prescription only) US: ℞-only EU: Rx-only
Pharmacokinetic data
Protein binding	Highly bound, no exact figure available
Metabolism	Liver (CYP3A4-mediated oxidation, also isomerised to tretinoin)
Elimination half-life	2–10 hours
Excretion	Urine (64%), faeces (30%)
Identifiers
IUPAC name (2E,4E,6Z,8E)-3,7-dimethyl-9-(2,6,6-trimethyl- 1-cyclohexenyl)nona-2,4,6,8-tetraenoic acid
CAS Number	5300-03-8
PubChem CID	449171
IUPHAR/BPS	2645
DrugBank	DB00523
ChemSpider	395778
UNII	1UA8E65KDZ
KEGG	D02815
ChEBI	CHEBI:50648
ChEMBL	ChEMBL705
CompTox Dashboard (EPA)	DTXSID6040404
ECHA InfoCard	100.111.081
Chemical and physical data
Formula	C20H28O2
Molar mass	300.442 g·mol
3D model (JSmol)	Interactive image
SMILES O=C(O)\C=C(\C=C\C=C(/C=C/C1=C(/CCCC1(C)C)C)C)C
InChI InChI=1S/C20H28O2/c1-15(8-6-9-16(2)14-19(21)22)11-12-18-17(3)10-7-13-20(18,4)5/h6,8-9,11-12,14H,7,10,13H2,1-5H3,(H,21,22)/b9-6+,12-11+,15-8-,16-14+ Key:SHGAZHPCJJPHSC-ZVCIMWCZSA-N
(verify)

Alitretinoin, or 9-cis-retinoic acid, is a form of vitamin A. It is also used in medicine as an antineoplastic (anti-cancer) agent developed by Ligand Pharmaceuticals. It is a first generation retinoid. Ligand gained Food and Drug Administration (FDA) approval for alitretinoin in February 1999.

Medical uses

Kaposi’s sarcoma

In the United States, topical alitretinoin is indicated for the treatment of skin lesions in AIDS-related Kaposi's sarcoma. Alitretinoin is not indicated when systemic therapy against Kaposi's sarcoma is required. It has received EMA (11 October 2000) and FDA (2 March 1999) approval for this indication.

Chronic hand eczema

Alitretinoin has been granted prescription rights in the UK (08/09/2008) for in chronic hand eczema as used by mouth. In May 2009 the National Institute for Health and Clinical Excellence (NICE) issued preliminary guidance on the use of alitretinoin for the treatment of severe chronic hand eczema in adults. The recommendation stated that only patients with severe chronic hand eczema who are unresponsive to potent topical corticosteroids, oral immunosuppressants or phototherapy should receive the drug. Final NICE guidance was expected in August 2009.

Adverse effects

Systemic use

Very common (> 10% frequency):

• Headache
• Hypertriglyceridemia
• High density lipoprotein decreased
• Hypercholesterolemia

Common (1–10% frequency):

• Anaemia
• Increased iron binding capacity
• Monocytes decreased
• Thrombocytes increased
• TSH decreased
• Free T4 decreased
• Flushing
• Conjunctivitis
• Dry eye
• Eye irritation
• Transaminase increased
• Dry skin
• Dry lips
• Cheilitis
• Eczema
• Dermatitis
• Erythema
• Hair loss
• Joint pain
• Muscle pains
• Blood creatine phosphokinase increased

Uncommon (0.1–1% frequency):

• Blurred vision
• Cataracts
• Nose bleeds
• Itchiness
• Rash
• Skin exfoliation
• Asteatotic eczema
• Exostosis
• Ankylosing spondylitis

Rare (< 0.1% frequency):

• Benign intracranial hypertension
• Vasculitis

Unknown frequency:

• Anaphylactic reactions
• Hypersensitivity
• Depression
• Mood changes
• Suicidal ideation
• Decreased night vision

Topical use

Very common (>10% frequency):

• Rash (77%)
• Pain (34%)
• Itchiness (11%)

Common (1-10% frequency):

• Exfoliative dermatitis
• Oedema
• Skin changes
• Paraesthesia

Contraindications

Pregnancy is an absolute contraindication as with most other vitamin A products, it should also be avoided when it comes to systemic use in any women that is of childbearing potential and not taking precautions to prevent pregnancy. Toctino (the oral capsule formulation of alitretinoin) contains soya oil and sorbitol. Patients who are allergic to peanut, soya or with rare hereditary fructose intolerance should not take this medicine. It is also contraindicated in nursing mothers. The oral formulation of alitretinoin is contraindicated in patients with:

• Hepatic insufficiency
• Severe chronic kidney disease
• Uncontrolled hypercholesterolemia
• Uncontrolled hypertriglyceridemia
• Uncontrolled hypothyroidism
• Hypervitaminosis A
• Hypersensitivity to any excipients in alitretinoin

Interactions

It is a CYP3A4 substrate and hence any inhibitor or inducer of this enzyme may alter plasma levels of alitretinoin. It should not be given to patients with excess vitamin A in their system as there is a potential for its actions on the retinoid X receptor to be exacerbated. It may also interact with tetracyclines to cause benign intracranial hypertension.

Overdose

Alitretinoin is a form of vitamin A. Alitretinoin has been administered in oncological clinical studies at dosages of more than 10-times of the therapeutic dosage given for chronic hand eczema. The adverse effects observed were consistent with retinoid toxicity, and included severe headache, diarrhoea, facial flushing and hypertriglyceridemia. These effects were reversible.

Mechanism of action

Alitretinoin is believed to be the endogenous ligand (a substance that naturally occurs in the body that activates this receptor) for retinoid X receptor, but it also activates the retinoic acid receptor.

References

1. ^ "Toctino 10mg and 30mg soft capsules - Summary of Product Characteristics (SPC)". electronic Medicines Compendium. Stiefel. 30 August 2013. Retrieved 1 February 2014.
2. "Panretin (Alitretinoin) Drug Information". RxList. November 21, 2000. Archived from the original on 18 December 2008. Retrieved 2009-01-14.
3. "Panretin : EPAR - Product Information" (PDF). European Medicines Agency. Eisai Ltd. 14 September 2012.
4. ^ "PANRETIN (alitretinoin) gel [Eisai Inc.]". DailyMed. Eisai Inc. March 2012. Retrieved 1 February 2014.
5. Ruzicka T, Larsen FG, Galewicz D, Horváth A, Coenraads PJ, Thestrup-Pedersen K, et al. (December 2004). "Oral alitretinoin (9-cis-retinoic acid) therapy for chronic hand dermatitis in patients refractory to standard therapy: results of a randomized, double-blind, placebo-controlled, multicenter trial". Archives of Dermatology. 140 (12): 1453–9. doi:10.1001/archderm.140.12.1453. PMID 15611422.
6. "NICE guidance documentation". Archived from the original on 2012-05-28. Retrieved 2009-05-07.
7. "Panretin, (alitretinoin topical), dosing, indications, interactions, adverse effects, and more". Medscape Reference. WebMD. Retrieved 1 February 2014.
8. Rowe A (February 1997). "Retinoid X receptors". The International Journal of Biochemistry & Cell Biology. 29 (2): 275–8. doi:10.1016/S1357-2725(96)00101-X. PMID 9147128.
9. Dawson MI, Xia Z (January 2012). "The retinoid X receptors and their ligands". Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids. 1821 (1): 21–56. doi:10.1016/j.bbalip.2011.09.014. PMC 4097889. PMID 22020178.

External links

• "Alitretinoin". Drug Information Portal. U.S. National Library of Medicine.

• Medicine

• Retinoids
• Antineoplastic drugs
• Cyclohexenes